MedinCell announces its participation in the Jefferies London Healthcare Conference 2022, 15-17 November in London 

November 9, 2022

 The conference will provide an opportunity to present to investors the recent and upcoming news from MedinCell, including : 

  • Refiling for approval of UzedyTM by its partner Teva, which has confirmed that it plans to commercialize it in the U.S. in the first half of 2023 
  • Launch by Teva of Phase 3 activities in the U.S. for a second treatment, mdc-TJK 
  • Launch by MedinCell’s partner, Arthitris Innovation Corporation (AIC), of Phase 3 activities for F14/mdc-CWM, a therapeutic first-in-class that aims to provide weeks of localized pain relief after Total Knee Replacement 
  • Advances in the experimental product portfolio at the formulation and pre-clinical stages 

Members of the MedinCell management will meet investors during individual meetings. 

Session en français

Rendez-vous le lundi 14 novembre à 18h00 (CET) pour une vidéoconférence dédiée aux récentes avancées des produits de notre portfeuille clinique

English session

On Monday 14, November at 6.00 pm (CET) participate in our videoconference dedicated to the latest news regarding our clinical and regulatory products

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.


  • This field is for validation purposes and should be left unchanged.